Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Kodiak Sciences Inc.
Kodiak Sciences Inc. News
Nov 13, 2025 - prnewswire.com
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Nov 12, 2025 - prnewswire.com
Kodiak Sciences to Present at Upcoming Investor Conferences
Nov 5, 2025 - prnewswire.com
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Oct 31, 2025 - youtube.com
The Big 3: GOOGL, KOD, FTK
Kodiak Sciences Inc. Quantitative Score
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Kodiak Sciences Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Kodiak Sciences Inc. Financials
Table Compare
Compare KOD metrics with: | |||
|---|---|---|---|
Earnings & Growth | KOD | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | KOD | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | KOD | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | KOD | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Kodiak Sciences Inc. Income
Kodiak Sciences Inc. Balance Sheet
Kodiak Sciences Inc. Cash Flow
Kodiak Sciences Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Kodiak Sciences Inc. Executives
| Name | Role |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer & President |
| Mr. John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer & Secretary |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development |
| Ms. Almas Qudrat M.Sc. | Chief Quality Officer |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer & President | 1973 | 1.31M | |
| Mr. John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer & Secretary | Male | 1962 | 795.8K |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development | 1972 | 300.71K | |
| Ms. Almas Qudrat M.Sc. | Chief Quality Officer | Female | -- | |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer | -- |
Kodiak Sciences Inc. Insider Trades
| Date | 4 Jul |
| Name | BORGESON JOHN A. |
| Role | See Remarks |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 250000 |
| Date | 4 Jul |
| Name | PERLROTH VICTOR |
| Role | Chairman and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 340000 |
| Date | 30 Jun |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | 30 Jun |
| Name | PROFUSEK ROBERT |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | 30 Jun |
| Name | Yang Taiyin |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Jul | BORGESON JOHN A. | See Remarks | Acquired | A-Award | 250000 |
| 4 Jul | PERLROTH VICTOR | Chairman and CEO | Acquired | A-Award | 340000 |
| 30 Jun | BAKER BROS. ADVISORS LP | Director, 10 percent owner | Acquired | A-Award | 40000 |
| 30 Jun | PROFUSEK ROBERT | Director | Acquired | A-Award | 40000 |
| 30 Jun | Yang Taiyin | Director | Acquired | A-Award | 40000 |